These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32339778)

  • 1. Dapsone and doxycycline could be potential treatment modalities for COVID-19.
    Farouk A; Salman S
    Med Hypotheses; 2020 Jul; 140():109768. PubMed ID: 32339778
    [No Abstract]   [Full Text] [Related]  

  • 2. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 3. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).
    Altschuler EL; Kast RE
    Med Hypotheses; 2020 Aug; 141():109774. PubMed ID: 32344275
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?
    Costiniuk CT; Jenabian MA
    Cytokine Growth Factor Rev; 2020 Jun; 53():63-65. PubMed ID: 32467020
    [No Abstract]   [Full Text] [Related]  

  • 5. Proposed use of thalidomide for the cytokine storm of COVID-19.
    Goihman-Yahr M
    Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614
    [No Abstract]   [Full Text] [Related]  

  • 6. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
    Abdulrab S; Al-Maweri S; Halboub E
    Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909
    [No Abstract]   [Full Text] [Related]  

  • 7. May IL-17 have a role in COVID-19 infection?
    Megna M; Napolitano M; Fabbrocini G
    Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19: Some clinical questions after the first 4 months.
    Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
    Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
    [No Abstract]   [Full Text] [Related]  

  • 9. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
    Jiménez-Brítez G; Ruiz P; Soler X
    Med Clin (Barc); 2020 Nov; 155(9):410-411. PubMed ID: 32718713
    [No Abstract]   [Full Text] [Related]  

  • 10. Tocilizumab administration in a refractory case of COVID-19.
    Dastan F; Nadji SA; Saffaei A; Tabarsi P
    Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
    [No Abstract]   [Full Text] [Related]  

  • 11. Should we unstress SARS-CoV-2 infected cells?
    Csukasi F; Rico G; Becerra J; Duran I
    Cytokine Growth Factor Rev; 2020 Aug; 54():3-5. PubMed ID: 32563554
    [No Abstract]   [Full Text] [Related]  

  • 12. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
    Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Mediated Coagulopathy in COVID-19 Infection.
    Vadasz Z; Brenner B; Toubi E
    Semin Thromb Hemost; 2020 Oct; 46(7):838-840. PubMed ID: 32877959
    [No Abstract]   [Full Text] [Related]  

  • 14. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
    Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
    Moutsopoulos HM
    Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
    [No Abstract]   [Full Text] [Related]  

  • 16. Alternative management of Covid-19 infection.
    Atrah HI
    Scott Med J; 2020 Aug; 65(3):72-75. PubMed ID: 32638647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.
    Dal Moro F; Livi U
    Clin Immunol; 2020 May; 214():108414. PubMed ID: 32272196
    [No Abstract]   [Full Text] [Related]  

  • 18. Colorectal surgery obesity-related morbidity during COVID-19.
    Montorfano L; Miret R; Rahman AU; Alonso M; Maron DJ; Roy M; Ferri F; Bejarano P; Wexner SD
    Surg Obes Relat Dis; 2020 Sep; 16(9):1372-1375. PubMed ID: 32723601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. After 62 years of regulating immunity, dexamethasone meets COVID-19.
    Cain DW; Cidlowski JA
    Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythema multiforme in the context of SARS-Coronavirus-2 infection.
    Sánchez-Velázquez A; Falkenhain D; Rivera Díaz R
    Med Clin (Barc); 2020 Aug; 155(3):141. PubMed ID: 32475615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.